<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metformin in the treatment of adults with type 2 diabetes mellitus</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metformin in the treatment of adults with type 2 diabetes mellitus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Metformin in the treatment of adults with type 2 diabetes mellitus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah J Wexler, MD, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In the absence of contraindications, <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> is considered the initial medication of choice for hyperglycemia in type 2 diabetes  (<a class="graphic graphic_table graphicRef56876" href="/d/graphic/56876.html" rel="external">table 1</a>). Metformin therapy (in the absence of contraindications) can be initiated, concurrent with lifestyle intervention, at the time of diabetes diagnosis [<a href="#rid1">1,2</a>].</p><p>The pharmacology, efficacy, contraindications, and side effects of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> for the treatment of diabetes will be reviewed here. A general discussion of initial treatment of type 2 diabetes and the role of metformin in the prevention of diabetes, in the treatment of polycystic ovary syndrome, and in gestational diabetes are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1774.html" rel="external">"Prevention of type 2 diabetes mellitus", section on 'Metformin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7411.html" rel="external">"Metformin for treatment of the polycystic ovary syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6790.html" rel="external">"Gestational diabetes mellitus: Glucose management and maternal prognosis", section on 'Metformin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph utd-adt-cnt utd-adt-pathwys">●</span><span class="utd-adt-cnt utd-adt-pathwys utd-content-120430">(Related Pathway(s):  <a class="utd-content-120430" href="/pathway/120430?topicRef=1809&amp;source=see_link">Diabetes: Initial therapy for non-pregnant adults with type 2 DM</a>.)</span></p><p></p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a>'s major effect is to decrease hepatic glucose output by inhibiting gluconeogenesis [<a href="#rid3">3-5</a>]. In addition, metformin increases insulin-mediated glucose utilization in peripheral tissues (such as muscle and liver), particularly after meals, and has an antilipolytic effect that lowers serum free fatty acid concentrations, thereby reducing substrate availability for gluconeogenesis [<a href="#rid6">6-8</a>]. As a result of the improvement in glycemia, serum insulin concentrations decline slightly [<a href="#rid9">9,10</a>]. Metformin has also been shown to decrease food intake and body weight [<a href="#rid11">11,12</a>].</p><p>The specific mechanisms underlying <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>'s effects remain incompletely understood [<a href="#rid13">13</a>]. Some evidence suggests that metformin suppresses gluconeogenesis by inhibiting a specific mitochondrial isoform of glycerophosphate dehydrogenase (mGPD), an enzyme responsible for converting glycerophosphate to dihydroxyacetone phosphate, thereby preventing glycerol from contributing to the gluconeogenic pathway [<a href="#rid14">14,15</a>]. In addition, inhibition of mGPD leads to accumulation of cytoplasmic NADH and a decrease in the conversion of lactate to pyruvate, limiting lactate contributions to hepatic gluconeogenesis. Excess glycerol and lactate are released into the plasma.</p><p><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> also activates the enzyme AMP-activated protein kinase (AMPK) in hepatocytes, which appears to be the mechanism by which metformin lowers serum lipid concentrations [<a href="#rid16">16,17</a>]. AMPK-dependent inhibitory phosphorylation of acetyl-CoA carboxylases Acc1 and Acc2 suppresses lipogenesis and lowers cellular fatty acid synthesis in liver and muscle [<a href="#rid18">18,19</a>]. Metformin works through the Peutz-Jeghers protein, LKB1, to regulate AMPK [<a href="#rid20">20</a>]. LKB1 is a tumor suppressor, and activation of AMPK through LKB1 may play a role in inhibiting cell growth [<a href="#rid21">21</a>]. (See <a class="local">'Cancer incidence'</a> below.)</p><p class="headingAnchor" id="H3889588303"><span class="h1">SUGGESTED APPROACH TO THE USE OF METFORMIN</span></p><p class="headingAnchor" id="H1559102"><span class="h2">Patient selection</span><span class="headingEndMark"> — </span>In the absence of specific contraindications, <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> is considered initial pharmacologic therapy for most patients with type 2 diabetes because of glycemic efficacy, absence of weight gain and hypoglycemia, general tolerability, long-term safety profile, and low cost  (<a class="graphic graphic_table graphicRef56876" href="/d/graphic/56876.html" rel="external">table 1</a>) [<a href="#rid1">1,2,22,23</a>]. It can be initiated at the time of diabetes diagnosis, along with consultation for lifestyle intervention. For highly motivated patients with glycated hemoglobin (A1C) near target (&lt;7.5 percent), a three- to six-month trial of lifestyle modification before initiating metformin is reasonable. Other options for initial therapy are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Choice of initial therapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comorbid conditions</strong> – In some patients with type 2 diabetes, comorbid conditions (eg, cardiovascular or kidney disease) provide a strong indication for another class of glucose-lowering agent (eg, glucagon-like peptide 1 [GLP-1] receptor agonist or sodium-glucose co-transporter 2 [SGLT2] inhibitor). Although some guidelines and experts endorse the initial use of these alternative agents as monotherapy or in combination with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> [<a href="#rid24">24,25</a>], we prefer initiating a single agent (typically metformin) and then sequentially adding additional glucose-lowering agents as needed, rather than starting with combination therapy. In the clinical trials that demonstrated the protective effects of GLP-1 receptor agonists and SGLT2 inhibitors, these agents were added to background metformin therapy in most participants.</p><p></p><p class="bulletIndent1">The effects of GLP-1 receptor agonists and SGLT2 inhibitors on cardiovascular and kidney outcomes are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Microvascular outcomes'</a> and  <a class="medical medical_review" href="/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Kidney outcomes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Without comorbid conditions</strong> – In patients with type 2 diabetes without comorbid conditions, hyperglycemia typically recurs after a successful initial response to <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>. Most patients require the addition of a second oral or an injectable agent. For patients who require additional therapy, a number of medication classes are available and can be used in combination with metformin. (See  <a class="medical medical_review" href="/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Our approach'</a>.)</p><p></p><p class="headingAnchor" id="H56212110"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> is contraindicated in patients with factors predisposing to lactic acidosis.</p><p>These predisposing factors/contraindications are:</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired kidney function (estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73 m<sup>2</sup>)</p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent active or progressive severe liver disease</p><p class="bulletIndent1"><span class="glyph">●</span>Active alcohol abuse</p><p class="bulletIndent1"><span class="glyph">●</span>Unstable or acute heart failure at risk of hypoperfusion</p><p class="bulletIndent1"><span class="glyph">●</span>Past history of lactic acidosis during <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased tissue perfusion or hemodynamic instability due to infection or other causes</p><p></p><p>The exact degree of kidney, cardiac, and liver function required for the safe use of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> remain uncertain [<a href="#rid26">26</a>]. Improved clinical outcomes with metformin have been reported in observational studies of patients with diabetes and heart failure [<a href="#rid27">27-29</a>], reduced kidney function (eGFR 45 to 60 mL/min/1.73 m<sup>2</sup>) [<a href="#rid29">29-31</a>], or chronic liver disease with hepatic impairment [<a href="#rid29">29</a>]. In one systematic review of 17 observational studies comparing regimens with and without metformin, metformin use was associated with lower all-cause mortality among patients with heart failure, renal impairment, or chronic liver disease with hepatic impairment [<a href="#rid29">29</a>]. In addition, metformin use in patients with renal impairment or heart failure was associated with fewer heart failure readmissions.</p><p>On the basis of these and other studies, the US Food and Drug Administration (FDA) revised its labeling of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, which previously had identified metformin as contraindicated in individuals with serum creatinine levels ≥1.4 mg/dL (124 micromol/L) and ≥1.5 mg/dL (133 micromol/L), respectively [<a href="#rid32">32</a>]. In the updated labeling, use of metformin is contraindicated in patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup>, and initiation of metformin is not recommended in patients with an eGFR between 30 and 45 mL/min/1.73 m<sup>2</sup>. For patients taking metformin whose eGFR falls below 45 mL/min/1.73 m<sup>2</sup>, the benefits and risk of continuing treatment should be assessed, whereas metformin should be discontinued if the eGFR falls below 30 mL/min/1.73 m<sup>2</sup>.</p><p>The following is our approach to the administration of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup>, we do not prescribe <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with an eGFR ≥45 mL/min/1.73 m<sup>2</sup>, we prescribe full dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with an eGFR of 30 to 44 mL/min/1.73 m<sup>2</sup>, some UpToDate authors and editors would not initiate <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, whereas others would initiate low-dose metformin (≤1000 mg per day) provided kidney function is stable (eg, no ongoing episode of acute kidney injury)  (<a class="graphic graphic_algorithm graphicRef142628" href="/d/graphic/142628.html" rel="external">algorithm 1</a>). Very limited data support the glycemic efficacy [<a href="#rid33">33,34</a>] and safety of the latter approach; lower doses of metformin may not provide desired glucose lowering and may not be safer. If metformin is initiated, kidney function should be monitored closely.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients taking <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> whose eGFR falls below 45 mL/min/1.73 m<sup>2</sup>, we reduce the metformin dose by half (no more than 1000 mg per day) with patient education to stop metformin for dehydration, nausea, or vomiting and more frequent testing of eGFR, although there are few data to support the efficacy and safety of this approach.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients taking <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> whose eGFR falls below 30 mL/min/1.73 m<sup>2</sup>, we discontinue metformin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We generally avoid <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> in patents with known or unknown conditions that cause acidosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We do not view stable compensated heart failure as a contraindication to <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We advise patients with an eGFR between 30 and 60 mL/min/1.73 m<sup>2</sup> or stable heart failure to stop taking <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> if they develop acute hypoxemia or any condition associated with acute hypoxemia, dehydration (eg, fasting or poor oral intake), or sepsis (eg, influenza, urinary tract infection) until the condition has resolved. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We do not view fatty liver disease generally as a contraindication unless there are major manifestations, such as reduced synthetic function or cirrhosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We prefer to hold <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> in patients who are about to receive intravenous iodinated contrast material (with potential for contrast-induced renal failure) if they are at increased risk for lactic acidosis independent of metformin. Such patients include those with vascular instability, hypotension, and potential hypoperfusion. Metformin should not be restarted until eGFR can be retested (usually two to five days after the procedure) and confirmed to be &gt;30 mL/min/1.73 m<sup>2</sup>.</p><p></p><p class="bulletIndent1">In addition, some UpToDate authors and editors discontinue <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> prior to any radiologic procedures with intravenous or intra-arterial contrast in patients with eGFR &lt;45 mL/min/1.73<sup> </sup>m<sup>2</sup>, since these patients are at higher risk for metformin-induced lactic acidosis if acute kidney injury were to develop. Metformin may be restarted several days after the procedure if the patient is back to a usual diet and activity level. In patients at high risk for acute kidney injury, renal function should be reassessed prior to resuming metformin.</p><p></p><p>The relationship among <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> use, intravenous contrast administration, and the occurrence of lactic acidosis is not well studied. The rationale for stopping metformin prior to intravenous iodinated contrast is to avoid the potential for high plasma metformin concentrations (and lactic acidosis) if the patient develops contrast-induced acute renal failure. In general, mortality in reported cases of metformin-induced lactic acidosis may be as high as 50 percent [<a href="#rid35">35</a>].</p><p>In a systematic review of studies and evidence-based guidelines on the use of intravenous contrast in patients taking <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, the only available data were from case reports and case series [<a href="#rid36">36</a>]. The majority of cases of metformin-related lactic acidosis occurred in patients with abnormal renal function who received intravenous contrast medium. The risk of metformin-induced lactic acidosis in patients with normal renal function who receive intravenous contrast is unknown but appears to be low.</p><p>The American College of Radiology suggests there is no need to discontinue <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> prior to or following the intravenous administration of iodinated contrast media in patients with no evidence of acute kidney injury and with eGFR ≥30 mL/min/1.73 m<sup>2</sup> [<a href="#rid37">37</a>]. This recommendation was presumably predicated on the increasing uncertainty regarding the role of contrast-dye procedures in acute kidney injury [<a href="#rid38">38</a>] and the overall rarity of lactic acidosis in metformin-treated patients (see <a class="local">'Lactic acidosis'</a> below). Until more data are available, however, and taking into account the morbidity and mortality of metformin-associated lactic acidosis, we prefer to hold metformin in patients at increased risk for lactic acidosis (eg, vascular instability, hypotension, potential hypoperfusion) independent of metformin, as described in the bullet above. (See  <a class="medical medical_review" href="/d/html/7241.html" rel="external">"Contrast-associated and contrast-induced acute kidney injury: Clinical features, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H4060810358"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>Prior to starting <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, we review serum creatinine (with eGFR), liver function tests, and A1C. The general evaluation for patients with newly diagnosed diabetes is reviewed separately. (See  <a class="medical medical_review" href="/d/html/1812.html" rel="external">"Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults", section on 'Comprehensive history'</a>.)</p><p class="headingAnchor" id="H2327929850"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>For initial dosing of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, we prefer immediate-release rather than extended-release preparations. Metformin is absorbed rapidly from the small intestine, with peak plasma concentrations attained in two hours. It is not bound to plasma proteins, is not metabolized, and is rapidly excreted in the urine [<a href="#rid39">39,40</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immediate-release </strong><strong>metformin</strong> – Immediate-release <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> is available as 500, 850, or 1000 mg tablets and should be taken with meals (to reduce gastrointestinal side-effects) twice daily.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with eGFR ≥45 mL/min/1.73 m<sup>2</sup>, we begin with 500 mg once daily with the evening meal and, if tolerated, add a second 500 mg dose with breakfast. The dose can be increased slowly (one tablet every one to two weeks) until reaching the usual effective dose (1500 to 2000 mg/day). In one seminal study, the maximum recommended dose of 2550 mg/day (850 mg three times daily) provided only marginally better glycemia lowering than 1500 or 2000 mg and was associated with a higher incidence of gastrointestinal side effects [<a href="#rid34">34</a>]; however, based on individual glycemic response and side effects, the maximum recommended dose may be beneficial.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with eGFR of 30 to 44 mL/min/1.73 m<sup>2</sup>, we begin with 500 mg once daily with the evening meal and, if tolerated, add a second 500 mg dose with breakfast. We do not increase the dose further (ie, no more than 1000 mg per day), although there are little or no data to support the glycemic efficacy and safety of this approach. We educate patients regarding the risk of taking <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> if acute kidney injury develops and the importance of discontinuation in situations that may increase this risk. We typically increase the frequency of kidney function monitoring. (See <a class="local">'Monitoring'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with eGFR &lt;30 mL/min/1.73 m<sup>2</sup>, <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> should not be prescribed. (See <a class="local">'Contraindications'</a> above.)</p><p></p><p class="bulletIndent1">For patients who have gastrointestinal intolerance of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, slower titration, ensuring that the patient is taking the medication with food, or switching to an extended-release formulation may improve tolerability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extended-release </strong><strong>metformin</strong> – Extended-release <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, typically taken once daily with the evening meal, is available in 500 and 750 mg tablets, as well as in an oral suspension (500 mg/5 mL). Patients may be switched from metformin to the once-daily, extended-release preparation at the same total daily dose, up to 2000 mg once daily. Since metformin should be taken with food, the ability to administer the entire dose once daily may promote adherence [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1">Randomized comparisons of immediate-release and extended-release <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> have demonstrated that the preparations are equally effective, with extended-release metformin having similar or slightly improved gastrointestinal tolerability [<a href="#rid42">42,43</a>].</p><p></p><p class="headingAnchor" id="H451063953"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>For patients taking <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, we measure:</p><p class="bulletIndent1"><span class="glyph">●</span>A1C every three to six months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine annually.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin B12 annually, particularly in individuals at risk for developing B12 deficiency due to decreased intake (eg, vegan diet) or absorption (eg, bariatric surgery). <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> lowers serum vitamin B12 concentrations in 5 to 10 percent of patients who have been taking metformin for five years. (See <a class="local">'Vitamin B12 deficiency'</a> below.)</p><p></p><p>General monitoring for glycemic management and diabetes-related complications is reviewed separately  (<a class="graphic graphic_table graphicRef63002" href="/d/graphic/63002.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Blood glucose monitoring and target A1C'</a> and  <a class="medical medical_review" href="/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Diabetes-related complications'</a>.)</p><p class="headingAnchor" id="H1145085961"><span class="h1">CLINICAL OUTCOMES</span></p><p class="headingAnchor" id="H3"><span class="h2">Glycemic efficacy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> is considered initial pharmacologic therapy for most patients with type 2 diabetes because of glycemic efficacy, absence of weight gain and hypoglycemia, general tolerability, and favorable cost  (<a class="graphic graphic_table graphicRef56876" href="/d/graphic/56876.html" rel="external">table 1</a>) [<a href="#rid44">44</a>]. In a now classic study, the United States Multicenter Metformin Study Group, for example, randomly assigned patients with type 2 diabetes and obesity who were above glycemic targets on diet alone to either metformin or placebo [<a href="#rid45">45</a>]. After 29 weeks, the mean A1C concentration was 7.1 percent in the metformin group as compared with 8.6 percent in the placebo group; these findings have been borne out in multiple subsequent trials.</p><p>The glycemic efficacy of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> is reviewed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Glycemic efficacy'</a>.)</p><p class="headingAnchor" id="H12029260"><span class="h2">Weight loss</span><span class="headingEndMark"> — </span>In individuals with obesity, <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> promotes modest weight reduction or at least weight stabilization  (<a class="graphic graphic_figure graphicRef55968" href="/d/graphic/55968.html" rel="external">figure 1</a>) [<a href="#rid9">9,46</a>]. This is in contrast to the weight gain often associated with insulin or sulfonylurea treatment [<a href="#rid9">9,46</a>]. In one large study, for example, patients treated with <a class="drug drug_general" data-topicid="8494" href="/d/drug information/8494.html" rel="external">glyburide</a> gained an average of 1.6 kg, whereas those receiving metformin lost 2.9 kg [<a href="#rid47">47</a>]. In a trial comparing metformin with a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist, <a class="drug drug_general" data-topicid="97148" href="/d/drug information/97148.html" rel="external">dulaglutide</a>, weight loss at 52 weeks was similar in the two groups (-2.29 and -2.22 kg for dulaglutide 1.5 mg and metformin, respectively) [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H25434233"><span class="h2">Cardiovascular effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> does not have adverse cardiovascular effects, and it appears to decrease cardiovascular events in certain populations [<a href="#rid44">44,49-54</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes and obesity who were assigned initially to receive <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> rather than sulfonylurea or insulin therapy had a decreased risk of the aggregate diabetes-related endpoint (endpoints included both macrovascular and microvascular complications) and all-cause mortality [<a href="#rid51">51</a>]. During the postinterventional observation period of the UKPDS, reductions in the risk of macrovascular complications were maintained in the metformin group [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/1760.html" rel="external">"Glycemic control and vascular complications in type 2 diabetes mellitus", section on 'Intensive glycemic control'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another trial, 390 patients treated with insulin were randomly assigned to <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> versus placebo [<a href="#rid49">49</a>]. After four years, mean A1C (7.5 versus 7.9 percent) and body weight (85 versus 90 kg) were significantly lower in the metformin group. In addition, there was a decrease in the risk of the secondary macrovascular endpoint, which was a composite of 13 vascular events including myocardial infarction (MI), heart failure, stroke, amputation, and sudden death (event rates 15 versus 18 percent, adjusted hazard ratio [HR] 0.6, 95% CI 0.4-0.9).</p><p></p><p>In a subsequent meta-analysis of 170 trials and 25 observational studies evaluating the effects of oral or injectable diabetes medications as monotherapy and in combination with other oral agents or insulin on cardiovascular mortality, intermediate outcomes (A1C, body weight, lipid profiles), and adverse events, <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> was associated with lower long-term cardiovascular mortality compared with sulfonylurea monotherapy (based upon findings from two randomized trials and three observational studies) [<a href="#rid44">44</a>]. </p><p>In one of the trials included in the meta-analysis, 304 Chinese patients with established coronary heart disease and type 2 diabetes were randomly assigned to <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> versus <a class="drug drug_general" data-topicid="8492" href="/d/drug information/8492.html" rel="external">glipizide</a> [<a href="#rid50">50</a>]. Lifestyle intervention and other treatment for coronary heart disease were similar in both groups. After three years, the mean achieved A1C level was similar (7 and 7.1 percent) in the two groups. However, body weight, waist circumference, and body mass index (BMI) were significantly lower in the metformin group. A similar proportion of patients in each group received insulin (30 and 25 patients in metformin and glipizide groups, respectively). After a median follow-up of five years, there were fewer cardiovascular events (composite of nonfatal MI [5 versus 6], stroke [10 versus 15], arterial revascularization [21 versus 25], or death from cardiovascular or any cause [7 versus 14]) in the metformin group (total events 43 versus 60; HR 0.54, 95% CI 0.3-0.9). The main limitation of this trial was the small number of events. However, the results support the use of metformin, particularly in patients with coronary heart disease.</p><p><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> has lipid-lowering activity, resulting in a decrease in serum triglyceride and free fatty acid concentrations, a small decrease in serum low-density lipoprotein (LDL) cholesterol concentrations, and a very modest increase in serum high-density lipoprotein (HDL) cholesterol concentrations [<a href="#rid10">10,39,56</a>].</p><p class="headingAnchor" id="H1559300"><span class="h2">Cancer incidence</span><span class="headingEndMark"> — </span>Observational data suggest that use of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> decreases cancer incidence [<a href="#rid57">57-59</a>]. In meta-analyses of predominantly case-control and cohort studies in patients with type 2 diabetes, use of metformin compared with nonuse or with use of other diabetes treatment was associated with a reduced risk of all cancers (relative risk [RR] 0.61, 95% CI 0.54-0.70) [<a href="#rid60">60,61</a>], colorectal cancer (RR 0.64, 95% CI 0.54-0.76) [<a href="#rid60">60-62</a>], and lower cancer mortality (RR 0.66, 95% CI 0.49-0.88) [<a href="#rid60">60,63,64</a>]. Among the meta-analyses, the summary effect estimates were similar. With the exception of colorectal cancer, there was significant heterogeneity among the individual studies. Allocation and time-lag bias (healthier and younger individuals with earlier-stage diabetes likelier to be using metformin) complicates interpretation of these findings.</p><p>In contrast to the observational data, a meta-analysis of randomized trials comparing <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> with a comparator (thiazolidinedione [TZD], sulfonylurea, dipeptidyl peptidase-4 [DPP-4] inhibitor, or placebo) did not show a reduction in cancer incidence [<a href="#rid65">65</a>]. The majority of the trials were not designed to explore cancer outcomes, which were not uniformly collected or adjudicated; therefore, malignancies were noted as serious adverse events. In addition, average follow-up for cancer outcomes was only four years. A longer interval may be required to adequately assess cancer outcomes. Thus, prospective clinical trial data are required to confirm or refute this protective effect.</p><p>A possible mechanism by which <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> may decrease cancer incidence is regulation of AMP-activated protein kinase (AMPK) through LKB1 [<a href="#rid20">20</a>]. LKB1 is a tumor suppressor, and activation of AMPK through LKB1 may play a role in inhibiting cell growth. Studies in <em>Caenorhabditis elegans </em>have suggested that inactivation of mTORC1 with subsequent inhibition of growth through induction of ACAD10 may explain the anticancer effects of metformin [<a href="#rid66">66</a>]. (See <a class="local">'Mechanism of action'</a> above.)</p><p class="headingAnchor" id="H6"><span class="h1">ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H2006162333"><span class="h2">Gastrointestinal</span><span class="headingEndMark"> — </span>The most common side effects of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> are gastrointestinal, including a metallic taste in the mouth, mild anorexia, nausea, abdominal discomfort, and soft bowel movements or diarrhea [<a href="#rid39">39</a>]. These symptoms are usually mild, transient, and reversible after dose reduction or discontinuation of the drug. They are minimized by taking the medication with food. In clinical trials, approximately 5 to 8 percent of study subjects discontinue metformin because of the gastrointestinal side effects [<a href="#rid67">67</a>].</p><p>Although <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> is generally well tolerated, patients taking metformin may develop gastrointestinal side effects even after many years of use. If gastrointestinal symptoms develop while taking metformin, we institute a metformin holiday, which may lead to resolution of symptoms. After a period of non-use, metformin may be successfully resumed at the same or a lower dose with a slow titration of the immediate-release or extended-release formulation.</p><p class="headingAnchor" id="H2189935888"><span class="h2">Vitamin B12 deficiency</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> reduces intestinal absorption of vitamin B12 in up to 30 percent of patients and lowers serum vitamin B12 concentrations in 5 to 10 percent, but it only rarely causes megaloblastic anemia (possibly due to <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> supplementation of the United States food supply) [<a href="#rid68">68,69</a>]. In some patients, vitamin B12 deficiency may present as peripheral neuropathy [<a href="#rid70">70</a>]. The dose and duration of use of metformin correlates with the risk of vitamin B12 deficiency [<a href="#rid69">69,71</a>]. In one study, the reduction in serum vitamin B12 appeared to be due to poor absorption of B12 in the ileum and was corrected by administration of oral <a class="drug drug_general" data-topicid="9185" href="/d/drug information/9185.html" rel="external">calcium carbonate</a> (1.2 g daily) [<a href="#rid72">72</a>]. In another study, supplementation with a daily multivitamin was associated with a lower prevalence of vitamin B12 deficiency [<a href="#rid73">73</a>].</p><p>Owing to data that suggest vitamin B12 deficiency is often asymptomatic and anemia is not a sensitive indicator, as well as a prevalence of vitamin B12 deficiency (or borderline low levels) in metformin-treated patients that may approach 20 percent over five years [<a href="#rid69">69</a>], routine B12 monitoring or administration is reasonable in patients with poor dietary intake, absorption, or long-term (&gt;5 years) <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> use. (See <a class="local">'Monitoring'</a> above.)</p><p class="headingAnchor" id="H7"><span class="h2">Lactic acidosis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence</strong> – The incidence of lactic acidosis in <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> users appears to be very low [<a href="#rid74">74,75</a>]. Despite its rarity, lactic acidosis related to metformin remains a concern because of the high case-fatality rate.</p><p></p><p class="bulletIndent1">In a systematic review of 347 randomized trials and prospective cohort studies representing 70,490 patient-years of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> use and 55,451 patient-years in the comparator group, there were no cases of lactic acidosis [<a href="#rid74">74</a>]. Almost one-half of the studies allowed inclusion of patients with a serum creatinine above 1.5 mg/dL (133 micromol/L), and almost all allowed inclusion of patients with at least one standard contraindication to metformin therapy. However, the number of patients who actually had these contraindications was not presented, and therefore, the safety of metformin in the presence of standard contraindications could not be assessed.</p><p></p><p class="bulletIndent1">In a subsequent retrospective cohort study evaluating the risk of hospitalization for acidosis in <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> users across the full spectrum of renal function, risk of acidosis was similar in metformin users and nonusers when estimated glomerular filtration rate (eGFR) was ≥30 mL/min/1.73 m<sup>2</sup> [<a href="#rid75">75</a>]. Lower eGFR was associated with a higher risk of acidosis in both metformin users and nonusers; however, there was an increased risk of acidosis in metformin users when eGFR was &lt;30 mL/min/1.73 m<sup>2</sup>. (See <a class="local">'Contraindications'</a> above.)</p><p></p><p class="bulletIndent1">Metformin-induced lactic acidosis can occur in patients with normal renal and hepatic function in the following clinical settings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Purposeful <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> overdose. (See  <a class="medical medical_review" href="/d/html/296.html" rel="external">"Metformin poisoning"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The genetic diabetes syndrome known as maternally inherited diabetes and deafness (MIDD), in which individuals are at increased risk of developing lactic acidosis with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> therapy. (See  <a class="medical medical_review" href="/d/html/1793.html" rel="external">"Classification of diabetes mellitus and genetic diabetic syndromes", section on 'Genetic defects in mitochondrial DNA'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intercurrent acute kidney injury from other causes. The presence of nausea, vomiting, or dehydration should prompt <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> discontinuation; metformin similarly may be withheld for fasting or poor oral intake to reduce the risk of lactic acidosis. (See  <a class="medical medical_review" href="/d/html/2370.html" rel="external">"Causes of lactic acidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predisposing factors</strong> – More serious lactic acid accumulation occurs in patients with conditions that predispose to hypoperfusion and hypoxemia (acute or progressive renal impairment, acute or progressive heart failure, acute pulmonary decompensation, sepsis, dehydration) [<a href="#rid39">39,76,77</a>]. This finding has resulted in the development of standard contraindications to <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, including significantly impaired renal function, heart failure, liver disease, and excessive alcohol intake. (See <a class="local">'Contraindications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The treatment of metformin-induced lactic acidosis is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/296.html" rel="external">"Metformin poisoning"</a>.)</p><p></p><p class="headingAnchor" id="H11742414"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104442.html" rel="external">"Society guideline links: Diabetes mellitus in adults"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy</strong> – In the absence of specific contraindications, we suggest <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> as initial therapy in most patients with type 2 diabetes (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>)  (<a class="graphic graphic_table graphicRef56876" href="/d/graphic/56876.html" rel="external">table 1</a>). Metformin is considered initial pharmacologic therapy over other diabetes drugs because of glycemic efficacy, absence of weight gain and hypoglycemia, general tolerability, and favorable cost. It can be initiated at the time of diabetes diagnosis, along with consultation for lifestyle intervention. For highly motivated patients with glycated hemoglobin (A1C) near target (&lt;7.5 percent), a three- to six-month trial of lifestyle modification before initiating metformin is reasonable. (See <a class="local">'Clinical outcomes'</a> above and  <a class="medical medical_review" href="/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Choice of initial therapy'</a> and  <a class="medical medical_review" href="/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'When to start'</a>.)</p><p></p><p class="bulletIndent1">In some patients with type 2 diabetes, comorbid conditions (eg, cardiovascular or kidney disease) provide a strong indication for another class of glucose-lowering agent (eg, glucagon-like peptide 1 [GLP-1] receptor agonist or sodium-glucose co-transporter 2 [SGLT2] inhibitor). Although some guidelines and experts endorse the initial use of these alternative agents as monotherapy or in combination with <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, we prefer initiating a single agent (typically metformin) and then sequentially adding additional glucose-lowering agents as needed, rather than starting with combination therapy. (See <a class="local">'Patient selection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications</strong> – <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> is contraindicated in patients with factors predisposing to lactic acidosis, including estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73 m<sup>2</sup>. Alternative initial treatment for patients with contraindications or intolerance to metformin is reviewed separately. (See <a class="local">'Contraindications'</a> above and  <a class="medical medical_review" href="/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Contraindications to or intolerance of metformin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>eGFR ≥45 mL/min/1.73 m</strong><strong><sup>2</sup></strong><strong> </strong>– For patients with an eGFR ≥45 mL/min/1.73 m<sup>2</sup>, we begin with 500 mg once daily with the evening meal and, if tolerated, add a second 500 mg dose with breakfast. The dose can be increased slowly (one tablet every one to two weeks) until reaching the usual effective dose (1500 to 2000 mg/day). (See <a class="local">'Dosing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>eGFR of 30 to 44 mL/min/1.73 m</strong><strong><sup>2</sup></strong> –<sup> </sup>For patients with an eGFR of 30 to 44 mL/min/1.73 m<sup>2</sup>, we typically reduce the <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> dose by half (ie, no more than 1000 mg per day)  (<a class="graphic graphic_algorithm graphicRef142628" href="/d/graphic/142628.html" rel="external">algorithm 1</a>). We educate patients regarding the risk of taking metformin if acute kidney injury develops and the importance of discontinuation in situations that may increase this risk. We typically increase the frequency of kidney function monitoring. (See <a class="local">'Dosing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – For patients taking <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>, we measure A1C every three to six months; serum creatinine annually; and vitamin B12 annually, particularly in patients at risk for vitamin B12 deficiency due to decreased intake (eg, vegan diet), absorption (eg, bariatric surgery), or long-term (&gt;5 years) metformin use. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common side effects of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> are gastrointestinal, including a metallic taste in the mouth, mild anorexia, nausea, abdominal discomfort, and soft bowel movements or diarrhea. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1">Lactic acidosis is an extremely uncommon side effect. However, it remains a concern because of the high case-fatality rate. Most cases have occurred in patients with conditions that predispose to hypoperfusion and hypoxemia (acute or progressive renal impairment, acute or progressive heart failure, acute pulmonary decompensation, sepsis, dehydration). (See <a class="local">'Lactic acidosis'</a> above.)</p><p></p><p class="headingAnchor" id="H2205280151"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David McCulloch, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42:S90.</a></li><li><a class="nounderline abstract_t">Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022; 65:1925.</a></li><li><a class="nounderline abstract_t">Jackson RA, Hawa MI, Jaspan JB, et al. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes 1987; 36:632.</a></li><li><a class="nounderline abstract_t">DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73:1294.</a></li><li><a class="nounderline abstract_t">Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia 2017; 60:1577.</a></li><li><a class="nounderline abstract_t">Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:550.</a></li><li><a class="nounderline abstract_t">McIntyre HD, Ma A, Bird DM, et al. Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus. Aust N Z J Med 1991; 21:714.</a></li><li><a class="nounderline abstract_t">Pernicova I, Korbonits M. Metformin--mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014; 10:143.</a></li><li><a class="nounderline abstract_t">United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310:83.</a></li><li><a class="nounderline abstract_t">Wu MS, Johnston P, Sheu WH, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990; 13:1.</a></li><li><a class="nounderline abstract_t">Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008; 121:149.</a></li><li><a class="nounderline abstract_t">Glueck CJ, Fontaine RN, Wang P, et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 2001; 50:856.</a></li><li><a class="nounderline abstract_t">LaMoia TE, Butrico GM, Kalpage HA, et al. Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis. Proc Natl Acad Sci U S A 2022; 119:e2122287119.</a></li><li><a class="nounderline abstract_t">Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014; 510:542.</a></li><li><a class="nounderline abstract_t">Ferrannini E. The target of metformin in type 2 diabetes. N Engl J Med 2014; 371:1547.</a></li><li><a class="nounderline abstract_t">Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108:1167.</a></li><li><a class="nounderline abstract_t">Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002; 51:2420.</a></li><li><a class="nounderline abstract_t">Fullerton MD, Galic S, Marcinko K, et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med 2013; 19:1649.</a></li><li><a class="nounderline abstract_t">Shaw RJ. Metformin trims fats to restore insulin sensitivity. Nat Med 2013; 19:1570.</a></li><li><a class="nounderline abstract_t">Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310:1642.</a></li><li><a class="nounderline abstract_t">Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways. Annu Rev Biochem 2006; 75:137.</a></li><li><a class="nounderline abstract_t">Qaseem A, Barry MJ, Humphrey LL, et al. Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med 2017; 166:279.</a></li><li><a class="nounderline abstract_t">Choi JG, Winn AN, Skandari MR, et al. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med 2022; 175:1392.</a></li><li><a class="nounderline abstract_t">ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S140.</a></li><li><a class="nounderline abstract_t">Abdul-Ghani MA, Puckett C, Triplitt C, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab 2015; 17:268.</a></li><li><a class="nounderline abstract_t">Huang W, Castelino RL, Peterson GM. Metformin usage in type 2 diabetes mellitus: are safety guidelines adhered to? Intern Med J 2014; 44:266.</a></li><li><a class="nounderline abstract_t">Khurana R, Malik IS. Metformin: safety in cardiac patients. Heart 2010; 96:99.</a></li><li><a class="nounderline abstract_t">Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 2013; 6:395.</a></li><li><a class="nounderline abstract_t">Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Ann Intern Med 2017; 166:191.</a></li><li><a class="nounderline abstract_t">Lu WR, Defilippi J, Braun A. Unleash metformin: reconsideration of the contraindication in patients with renal impairment. Ann Pharmacother 2013; 47:1488.</a></li><li><a class="nounderline abstract_t">Ekström N, Schiöler L, Svensson AM, et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open 2012; 2.</a></li><li class="breakAll">http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494829.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery (Accessed on April 11, 2016).</li><li><a class="nounderline abstract_t">Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014; 312:2668.</a></li><li><a class="nounderline abstract_t">Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103:491.</a></li><li><a class="nounderline abstract_t">Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998; 338:265.</a></li><li><a class="nounderline abstract_t">Goergen SK, Rumbold G, Compton G, Harris C. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology 2010; 254:261.</a></li><li class="breakAll">https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf (Accessed on July 14, 2021).</li><li><a class="nounderline abstract_t">McDonald JS, McDonald RJ, Comin J, et al. Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis. Radiology 2013; 267:119.</a></li><li><a class="nounderline abstract_t">Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574.</a></li><li><a class="nounderline abstract_t">Schäfer G. Biguanides. A review of history, pharmacodynamics and therapy. Diabete Metab 1983; 9:148.</a></li><li><a class="nounderline abstract_t">Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab 2009; 11:338.</a></li><li><a class="nounderline abstract_t">Aggarwal N, Singla A, Mathieu C, et al. Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes. Diabetes Obes Metab 2018; 20:463.</a></li><li><a class="nounderline abstract_t">Schwartz S, Fonseca V, Berner B, et al. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006; 29:759.</a></li><li><a class="nounderline abstract_t">Maruthur NM, Tseng E, Hutfless S, et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 164:740.</a></li><li><a class="nounderline abstract_t">DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333:541.</a></li><li><a class="nounderline abstract_t">Hemmingsen B, Schroll JB, Wetterslev J, et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open 2014; 2:E162.</a></li><li><a class="nounderline abstract_t">Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427.</a></li><li><a class="nounderline abstract_t">Umpierrez G, Tofé Povedano S, Pérez Manghi F, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 2014; 37:2168.</a></li><li><a class="nounderline abstract_t">Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009; 169:616.</a></li><li><a class="nounderline abstract_t">Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013; 36:1304.</a></li><li><a class="nounderline abstract_t">Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854.</a></li><li><a class="nounderline abstract_t">Roumie CL, Chipman J, Min JY, et al. Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function. JAMA 2019; 322:1167.</a></li><li><a class="nounderline abstract_t">Han Y, Xie H, Liu Y, et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol 2019; 18:96.</a></li><li><a class="nounderline abstract_t">Li T, Providencia R, Jiang W, et al. Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases. Drugs 2022; 82:311.</a></li><li><a class="nounderline abstract_t">Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577.</a></li><li><a class="nounderline abstract_t">Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15:755.</a></li><li><a class="nounderline abstract_t">Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32:1620.</a></li><li><a class="nounderline abstract_t">Monami M, Lamanna C, Balzi D, et al. Sulphonylureas and cancer: a case-control study. Acta Diabetol 2009; 46:279.</a></li><li><a class="nounderline abstract_t">Landman GW, Kleefstra N, van Hateren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33:322.</a></li><li><a class="nounderline abstract_t">Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012; 7:e33411.</a></li><li><a class="nounderline abstract_t">Soranna D, Scotti L, Zambon A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 2012; 17:813.</a></li><li><a class="nounderline abstract_t">Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2011; 34:2323.</a></li><li><a class="nounderline abstract_t">Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist 2013; 18:1248.</a></li><li><a class="nounderline abstract_t">Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol 2016; 27:2184.</a></li><li><a class="nounderline abstract_t">Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012; 55:2593.</a></li><li><a class="nounderline abstract_t">Wu L, Zhou B, Oshiro-Rapley N, et al. An Ancient, Unified Mechanism for Metformin Growth Inhibition in C. elegans and Cancer. Cell 2016; 167:1705.</a></li><li><a class="nounderline abstract_t">GRADE Study Research Group, Nathan DM, Lachin JM, et al. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med 2022; 387:1063.</a></li><li><a class="nounderline abstract_t">de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010; 340:c2181.</a></li><li><a class="nounderline abstract_t">Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 2016; 101:1754.</a></li><li><a class="nounderline abstract_t">Bell DS. Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. South Med J 2010; 103:265.</a></li><li><a class="nounderline abstract_t">Ting RZ, Szeto CC, Chan MH, et al. Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch Intern Med 2006; 166:1975.</a></li><li><a class="nounderline abstract_t">Bauman WA, Shaw S, Jayatilleke E, et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 2000; 23:1227.</a></li><li><a class="nounderline abstract_t">Pflipsen MC, Oh RC, Saguil A, et al. The prevalence of vitamin B(12) deficiency in patients with type 2 diabetes: a cross-sectional study. J Am Board Fam Med 2009; 22:528.</a></li><li><a class="nounderline abstract_t">Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; :CD002967.</a></li><li><a class="nounderline abstract_t">Lazarus B, Wu A, Shin JI, et al. Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study. JAMA Intern Med 2018; 178:903.</a></li><li><a class="nounderline abstract_t">Gan SC, Barr J, Arieff AI, Pearl RG. Biguanide-associated lactic acidosis. Case report and review of the literature. Arch Intern Med 1992; 152:2333.</a></li><li><a class="nounderline abstract_t">Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res 1994; 30:187.</a></li></ol></div><div id="topicVersionRevision">Topic 1809 Version 59.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30559235" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36151309" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3552795" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mechanism of metformin action in non-insulin-dependent diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1955512" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28776086" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The mechanisms of action of metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7623903" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1759920" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24393785" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Metformin--mode of action and clinical implications for diabetes and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7833731" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2404714" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18261504" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Meta-analysis: metformin treatment in persons at risk for diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11436194" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35238637" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24847880" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25317875" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The target of metformin in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11602624" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Role of AMP-activated protein kinase in mechanism of metformin action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12145153" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24185692" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24309653" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Metformin trims fats to restore insulin sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16308421" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16756488" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : LKB1-dependent signaling pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28055075" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36191315" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36507650" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25425451" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24405767" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Metformin usage in type 2 diabetes mellitus: are safety guidelines adhered to?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19564648" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Metformin: safety in cardiac patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23508758" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28055049" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24259604" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Unleash metformin: reconsideration of the contraindication in patients with renal impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22798258" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22798258" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25536258" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Metformin in patients with type 2 diabetes and kidney disease: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9428832" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9441244" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Lactic acidosis in patients with diabetes treated with metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20032157" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20032157" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23319662" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8569826" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6352352" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Biguanides. A review of history, pharmacodynamics and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19267712" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28857388" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567811" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27088241" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7623902" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25295236" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17145742" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24842985" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19307526" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23230096" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9742977" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31536102" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31362743" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35032305" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18784090" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : 10-year follow-up of intensive glucose control in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1600835" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Biguanides and NIDDM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19564453" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19082520" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sulphonylureas and cancer: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19918015" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22448244" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22643536" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21949223" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24258613" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27681864" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22875195" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27984722" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : An Ancient, Unified Mechanism for Metformin Growth Inhibition in C. elegans and Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36129996" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20488910" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26900641" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20134380" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17030830" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Risk factors of vitamin B(12) deficiency in patients receiving metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10977010" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19734399" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The prevalence of vitamin B(12) deficiency in patients with type 2 diabetes: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393934" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29868840" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1444694" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Biguanide-associated lactic acidosis. Case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7862618" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Re-evaluation of a biguanide, metformin: mechanism of action and tolerability.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
